These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21865314)

  • 1. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment.
    Seet RC; Rabinstein AA
    QJM; 2012 Jan; 105(1):69-75. PubMed ID: 21865314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posterior reversible encephalopathy syndrome after intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to age-related maculopathy.
    Artunay O; Yuzbasioglu E; Rasier R; Sengul A; Bahcecioglu H
    J Ocul Pharmacol Ther; 2010 Jun; 26(3):301-3. PubMed ID: 20565319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient.
    Abbas O; Shamseddin A; Temraz S; Haydar A
    BMJ Case Rep; 2013 Feb; 2013():. PubMed ID: 23436889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posterior Reversible Encephalopathy Syndrome in Patients With Cancer.
    Singer S; Grommes C; Reiner AS; Rosenblum MK; DeAngelis LM
    Oncologist; 2015 Jul; 20(7):806-11. PubMed ID: 26032137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatal posterior revesible leukoencephalopathy syndrome associated coma induced by bevacizumab in metastatic colorectal cancer and review of literature.
    Eryılmaz MK; Mutlu H; Salim DK; Musri FY; Coşkun HŞ
    J Oncol Pharm Pract; 2016 Dec; 22(6):806-810. PubMed ID: 26467267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posterior reversible encephalopathy syndrome associated with deoxycoformycin and alemtuzumab.
    Cooksley T; Haji-Michael P
    J R Coll Physicians Edinb; 2011 Sep; 41(3):215-7. PubMed ID: 21949916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Posterior Reversible Encephalopathy Syndrome (PRES): About 4 cases].
    Chanal E; Bouleftour W; Rivoirard R; Bosaki C; Forges F; Jacquin JP; Fournel P; Mery B; Saban-Roche L
    Presse Med; 2019 Oct; 48(10):1026-1031. PubMed ID: 31653541
    [No Abstract]   [Full Text] [Related]  

  • 8. Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.
    Lou E; Turner S; Sumrall A; Reardon DA; Desjardins A; Peters KB; Sampson JH; Friedman HS; Vredenburgh JJ
    J Clin Oncol; 2011 Oct; 29(28):e739-42. PubMed ID: 21900098
    [No Abstract]   [Full Text] [Related]  

  • 9. Electrographic patterns in patients with posterior reversible encephalopathy syndrome and seizures.
    Kamiya-Matsuoka C; Tummala S
    J Neurol Sci; 2017 Apr; 375():294-298. PubMed ID: 28320152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posterior reversible encephalopathy syndrome with bevacizumab.
    Lau PC; Paunipagar B
    Hong Kong Med J; 2011 Feb; 17(1):80-1. PubMed ID: 21282833
    [No Abstract]   [Full Text] [Related]  

  • 11. Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab.
    Peter S; Hausmann N; Schuster A; Boehm HF
    Clin Exp Ophthalmol; 2008; 36(1):94-6. PubMed ID: 18290962
    [No Abstract]   [Full Text] [Related]  

  • 12. Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: a case report and literature review.
    Femia G; Hardy TA; Spies JM; Horvath LG
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):115-22. PubMed ID: 22524570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study.
    Kamiya-Matsuoka C; Paker AM; Chi L; Youssef A; Tummala S; Loghin ME
    J Neurooncol; 2016 May; 128(1):75-84. PubMed ID: 26900076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.
    Tlemsani C; Mir O; Boudou-Rouquette P; Huillard O; Maley K; Ropert S; Coriat R; Goldwasser F
    Target Oncol; 2011 Dec; 6(4):253-8. PubMed ID: 22090260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posterior reversible encephalopathy syndrome possibly induced by pemetrexed maintenance therapy for lung cancer: a case report and literature review.
    Smets GJ; Loyson T; Van Paesschen W; Demaerel P; Nackaerts K
    Acta Clin Belg; 2018 Oct; 73(5):382-388. PubMed ID: 29173113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posterior Reversible Encephalopathy Syndrome (PRES) Presenting as Status Epilepticus: A Case Report and Literature Review.
    Sharma P; Abbas MK; Huynh M
    Conn Med; 2016 Sep; 80(8):475-478. PubMed ID: 29782783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer.
    Sclafani F; Giuseppe G; Mezynksi J; Collins C; Crown J
    J Clin Oncol; 2012 Sep; 30(26):e257-9. PubMed ID: 22649141
    [No Abstract]   [Full Text] [Related]  

  • 18. Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer.
    Wang W; Zhao LR; Lin XQ; Feng F
    World J Gastroenterol; 2014 Jun; 20(21):6691-7. PubMed ID: 24914397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Reversible posterior leukoencephalopathy syndrome associated to bevacizumab].
    Ortiz-Lopez EM; Gonzalez-Nieto JA; Rojas-Marcos I; Blanco-Ollero A
    Rev Neurol; 2010 Jul; 51(2):117-8. PubMed ID: 20602317
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical predictors and differential diagnosis of posterior reversible encephalopathy syndrome.
    Faille LD; Fieuws S; Van Paesschen W
    Acta Neurol Belg; 2017 Jun; 117(2):469-475. PubMed ID: 28144796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.